scholarly journals Caring for the long-term survivor after allogeneic stem cell transplantation

Hematology ◽  
2014 ◽  
Vol 2014 (1) ◽  
pp. 495-503 ◽  
Author(s):  
Smita Bhatia

Abstract Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk of developing long-term complications such as subsequent malignancies and cardiopulmonary compromise. The prevalence of chronic health conditions approaches 75% among allogeneic HCT survivors and that for severe or life-threatening conditions exceeds 20%. This chapter describes the burden of morbidity carried by HCT survivors to help healthcare providers and policy makers understand the scope of the problem and the need for life-long follow-up and proactive care for this vulnerable population.

Blood ◽  
2010 ◽  
Vol 116 (17) ◽  
pp. 3129-3139 ◽  
Author(s):  
Can-Lan Sun ◽  
Liton Francisco ◽  
Toana Kawashima ◽  
Wendy Leisenring ◽  
Leslie L. Robison ◽  
...  

Abstract Long-term survival is now an expected outcome after hematopoietic cell transplantation (HCT). However, the burden of morbidity long-term after HCT remains unknown. We examined the magnitude of risk of chronic health conditions reported by 1022 HCT survivors and their siblings (n = 309). A severity score (grades 1 [mild] through 4 [life-threatening]) was assigned to each health condition using the Common Terminology Criteria for Adverse Events, Version 3. Sixty-six percent of the HCT survivors reported at least one chronic condition; 18% reported severe/life-threatening conditions; comparable values in siblings were 39% and 8%, respectively (P < .001). The cumulative incidence of a chronic health condition among HCT survivors was 59% (95% confidence interval [CI], 56%-62%) at 10 years after HCT; for severe/life-threatening conditions or death from chronic health conditions, the 10-year cumulative incidence approached 35% (95% CI, 32%-39%). HCT survivors were twice as likely as siblings to develop a chronic condition (95% CI, 1.6-2.1), and 3.5 times to develop severe/life-threatening conditions (95% CI, 2.3-5.4). HCT survivors with chronic graft-versus-host disease were 4.7 times as likely to develop severe/life-threatening conditions (95% CI, 3.0-7.2). The burden of long-term morbidity borne by HCT survivors is substantial, and long-term follow-up of patients who received transplantation is recommended.


2021 ◽  
Vol 10 (2) ◽  
pp. 113-117
Author(s):  
Toshiki Mushino ◽  
Akinori Nishikawa ◽  
Yoshikazu Hori ◽  
Hideki Kosako ◽  
Yuichi Tochino ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5534-5534
Author(s):  
Moaath Mustafa Ali ◽  
Donna M Abounader ◽  
Lisa A. Rybicki ◽  
Jamie Starn ◽  
Christina Ferraro ◽  
...  

Abstract Allogeneic hematopoietic cell transplantation (alloHCT) is a curative therapy for high-risk acute lymphoblastic leukemia (ALL). However, long-term outcomes after alloHCT for adult ALL have not been well described. We conducted a retrospective cohort study of 72 consecutive adult ALL patients who underwent a first myeloablative alloHCT at our institution from January 2000-December 2013. Median age at HCT was 38 yrs (range, 18-62), 40 (56%) were male, 18 (38%) had high HCT CI score, 14 (19%) had prior CNS leukemia and 35 (49%) had BCR-ABL+ disease. Donor source was HLA-matched related donor for 50% patients and 90% received PBSC as graft source. All patients were transplanted in CR (72% were in 1st or 2nd CR) and 92% received T-cell replete grafts. Median time from diagnosis to alloHCT was 5 months (range, 2-90). The incidences of grade II-IV and III-IV acute GvHD, chronic GvHD and extensive chronic GvHD were 43%, 13%, 51% and 36%, respectively. The median follow-up for our cohort is 76 months. At 6 years after HCT, probability of overall survival (OS) was 33% (95% CI, 21-44%) and relapse-free survival (RFS) was 30% (95% CI, 19-42%), and the cumulative incidence of relapse was 36% (95% CI, 25-48%) and non-relapse mortality (NRM) was 37% (95% CI, 26-49%). The most common causes of death were relapse (43%) and infection (21%); majority of relapses occurred within the first 2-years post-transplantation. There were no second cancer related deaths. In multivariable analyses, factors significantly associated with OS were HCT CI score (HR 2.69 for high vs. low/int., P=0.002) and CMV status (HR 2.62 for donor+ vs. others, P=0.05). HCT CI score was the only predictive factor for RFS (HR 2.26 for high, P=0.007). We also compared outcomes by BCR-ABL status. BCR-ABL+ patients were older (median age 42 vs. 36 yrs, p=0.02), had low HCT CI score (34% vs 22%, p=0.01), were more likely to be in CR1 (74% vs. 32%, p=0.002), and as a result, proceeded to HCT sooner after diagnosis (median 4 vs 7 months, p=<0.001). For BCR-ABL+ and BCR-ABL- patients, 6 year OS was 41% and 25%, RFS was 40% and 21%, relapse was 27% and 45% and NRM was 38% and 36% (P=NS for all comparisons). Myeloablative alloHCT can provide long-term survival for selected high-risk adult ALL patients. Relapses are relatively uncommon after 2 years post-transplant. Long-term NRM is high in this population and we did not observe a plateau in its incidence until 7.5 years post-transplant, suggesting the need for long-term follow up to prevent and manage late complications of alloHCT. Figure 1. Figure 1. Disclosures Majhail: Gamida Cell Ltd.: Consultancy; Anthem Inc.: Consultancy.


Author(s):  
D. Wegener ◽  
P. Lang ◽  
F. Paulsen ◽  
N. Weidner ◽  
D. Zips ◽  
...  

Abstract Purpose This retrospective analysis aims to address the toxicity and efficacy of a modified total nodal irradiation (TNI)-based conditioning regimen before haploidentical hematopoietic cell transplantation (HCT) in pediatric patients. Materials and methods Patient data including long-term follow-up were evaluated of 7 pediatric patients with malignant (n = 2) and non-malignant diseases (n = 5) who were treated by a primary TNI-based conditioning regimen. TNI was performed using anterior/posterior opposing fields. All patients received 7 Gy single-dose TNI combined with systemic agents followed by an infusion of peripheral blood stem cells (n = 7). All children had haploidentical family donors. Results Engraftment was reached in 6/7 children after a median time of 9.5 days; 1 child had primary graft failure but was successfully reconditioned shortly thereafter. After an average follow-up time of 103.5 months (range 8.8–138.5 months), event-free (EFS) and overall survival (OS) rates were 71.4% and 85.7%, respectively. One child with a non-malignant disease died 8.8 months after transplantation due to a relapse and a multiple organ failure. Follow-up data was available for 5/6 long-term survivors with a median follow-up (FU) of 106.2 months (range 54.5–138.5 months). Hypothyroidism and deficiency of sexual hormones was present in 3/5 patients each. Mean forced expiratory volume in 1 s (FEV1) after TNI was 71%; mean vital capacity (VC) was 78%. Growth failure (< 10th percentile) occurred in 2/5 patients (height) and 1/5 patient (weight). No secondary malignancies were reported. Conclusion In this group of patients, a primary single-dose 7 Gy TNI-based conditioning regimen before HCT in pediatric patients allowed sustained engraftment combined with a tolerable toxicity profile leading to long-term OS/EFS. Late toxicity after a median FU of over 9 years includes growth failure, manageable hormonal deficiencies, and acceptable decrease in lung function.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 7033-7033
Author(s):  
S. G. Naik ◽  
R. Negrin ◽  
G. Laport ◽  
D. Miklos ◽  
J. Shizuru ◽  
...  

7033 Patients (pts) with high risk (HR) or advanced myeloid malignancies have limited effective treatment options. These include high-dose therapy followed by allogeneic hematopoietic cell transplantation (HCT). We report a single institution long-term follow-up of 96 pts, median age 50 (20–60) yrs, who received HLA matched related HCT between 1992 and 2007. All pts were treated with a uniform preparatory regimen: busulfan 16.0 mg/kg (d-8 to-5), etoposide 60mg/kg (d-4), cyclophosphamide 60mg/kg (d-2), and graft-versus-host-disease (GVHD) prophylaxis of cyclosporine and prednisone. Disease status at transplantation was induction failure (IF) acute myeloid leukemia (AML) (n = 10), HR AML in 1st complete remission (CR1) n = 11, in CR2 (n = 5), in CR3 (n = 2), relapsed refractory (RR) AML (n = 14), chronic myeloid leukemia (CML) in second chronic phase (n = 6), blast crisis (n = 2), myelofibrosis (n = 6), myeloproliferative disorders (n = 2), and MDS (n = 38). Thirty-six % (n = 35) of pts received bone marrow while 64 % (n = 61) received G-CSF mobilized peripheral blood mononuclear cells (PBMC). With a median follow up of 5.6 yrs (1.6–14.6 yrs) actuarial 5-year overall survival (OS) was 32% (95% CI 22–42%) and 5-year probability for freedom from progression (FFP) was 64% (95% CI 52%-76%). Relapse rate was 32% at 1 year and remained at 36% (95%CI 24%-48%) at 2 and 5 years with no further increase in relapse beyond two years. Non-relapse mortality (NRM) was 29 % (95% CI 20%5–38%) at day 100 and 39% (95% CI 29%-49%) at one yr. Cumulative incidence of acute (grade 3–4) and chronic GVHD was 28% (95% CI 19%-37%) and 38% (95% CI 24%-52%), respectively. There was no statistically significant difference in OS; 31% versus 32% (p = 0.89) or FFP 71% versus 60% (p = 0.29) for recipients of BM versus PBMC with similar results in IF and RR AML. These results confirm that pts with high-risk or advanced myeloid malignancies can achieve long-term survival following myeloablative allogeneic HCT with aggressive conditioning. Relapse and acute GVHD remain significant causes of mortality. Strategies to augment graft-versus-tumor reactions and reduce GVHD remain essential for improving long-term outcomes. No significant financial relationships to disclose.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4351-4351
Author(s):  
Rachel Phelan ◽  
Paul J Orchard ◽  
Margaret Semrud-Clikeman ◽  
Nicholas Smiley ◽  
Weston P Miller

Abstract Background: Allogeneic hematopoietic cell transplantation (HCT) remains standard therapy for various rare, inherited metabolic diseases (IMD). As survival improves, assessment of long-term outcomes is often hampered by patient attrition and distance from treating centers. We piloted a methodology to remotely study parental and/or patient perspectives of adaptive, behavioral, emotional and executive functioning in IMD. Patients and Methods: The University of Minnesota BMT Database was queried for surviving IMD patients and disease and transplant characteristics. Parents/patients were invited for study participation. The Research Electronic Data Capture (REDCapª) system was used to electronically administer and retrieve standard and custom survey tools in a one-time cross-sectional analysis (see Table 1). Parents were also asked about their satisfaction with the HCT process/outcomes. Finally, respondents rated independent performance of various activities of daily living (ADL). A Chi-square analysis was performed comparing survey results across post-HCT follow-up tertiles (recent, 1 to 6 years; intermediate, 6 to 16 years; and distant, 16 to 33 years). Results: We identified 421 patients transplanted for IMD between 1982 and 2015. Of 239 survivors, 69 (29%) were enrolled (patient only respondents = 3; parent only respondents = 46; both parent/patient respondents = 20). IMD diagnoses included Hurler syndrome (33), adrenoleukodystrophy (17), osteopetrosis (6), metachromatic leukodystrophy (5), and other (8). Forty-seven patients (68%) were male; the median age at HCT was 1.8 years (IQR, 1.1 to 6.5; range, 0.1 to 33.2). Sixty patients (87%) underwent myeloablative conditioning. The stem cell source was UCB in 28 (41%), marrow in 40 (58%) and PBSC in 1 (1%); 52 (75%) received an unrelated graft. Complete donor chimerism was seen in 70%, while 13% were 90-99% engrafted, 9% were 60-89% engrafted, and in 7% of cases engraftment was <60%. The median time from transplant to assessment was 9.2 years (IQR, 3.4 to 17.6; range, 1.1 to 32.8). Table 1 demonstrates results of a number of the administered tools. Across all administered standardized assessments of executive, emotional and adaptive behavioral functioning (BASC-2, BRIEF, VABS) the majority of patients demonstrated average skills and behaviors when compared to norms for age and gender. A sizable minority showed difficulty on the BASC-2 adaptive skills index with significantly greater difficulty with further time from transplant (p < 0.05). Those with Hurler Syndrome were most likely to be able to attend school, but most required an Individualized Education Plan (IEP). Patients with osteopetrosis showed the most problems with ADLs. Families mostly agreed (88%) that "HCT improved quality of life" for their child and nearly universally endorsed (95%) that "knowing what [they] do now, [they] would choose HCT for [their] child again." Conclusions: Effective, remote assessment of adaptive, behavioral, emotional and executive function via electronic methods is feasible in a large cohort of IMD patients surviving HCT. At a median follow-up of 9.2 years from HCT, the majority of studied patients had average functioning despite their underlying illness. While patients and their families continue to be impacted by complications of IMD following transplant, they were overall satisfied with the outcomes. Continued follow-up of this patient population is critical to provide appropriate counseling for patients and families considering HCT as a treatment option for IMD. Table 1. Performance on Standard Measures of Adaptive, Behavioral, Emotional and Executive Functioning for IMD Cohort after HCT Diagnosis BASC-Adaptive Skills BASC- Behavioral Symptoms Index BASC- Emotional Symptoms Index BRIEF- Global Executive Composite VABS-Maladaptive Behavior Index AA/A AR/CS AA/A AR/CS AA/A AR/CS AA/A AR/CS A E CS ALD (%) 44 56 78 22 67 33 63 37 50 40 10 HS (%) 67 33 90 10 100 0 69 31 61 33 6 OP (%) 80 20 100 0 0 0 100 0 100 0 0 Other (%) 67 33 84 16 100 0 67 33 63 25 12 All (%) 63 37 88 12 89 11 69 31 61 31 8 ALD = adrenoleukodystrophy; HS = Hurler Syndrome; OP = Osteopetrosis; AA = Above Average; A = Average; AR = At Risk; CS = Clinically Significant; E = Elevated Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4644-4644
Author(s):  
Ali Baghian ◽  
Reinhold Munker ◽  
Yordanka Koleva ◽  
Gunita Matharoo ◽  
Patricia Andrews ◽  
...  

Abstract Background: The prognosis of multiple myeloma (MM) has improved significantly over the last 20 years due to the introduction of autologous stem cell transplantation and novel drugs. The standard regimen for conditioning in MM is melphalan 200 mg/m2, since a study published in 2002 (Moreau et al.) showed a survival advantage of melphalan (MEL) only over melphalan- total body irradiation (MEL-TBI) conditioning. Ionizing radiation is an independent treatment modality and has activity in MM. We decided to reevaluate the outcome of MEL-TBI conditioning in the age of novel drugs. Patients and Methods: In a retrospective chart review, we identified 50 patients with MM who underwent autologous hematopoietic cell transplantation at Tulane University Medical Center and were conditioned with MEL-TBI between December 1995 and March 2012. Stem cells were collected following a stimulation by 10 µg/ kg filgrastim for 4 days. In case of insufficient collection, plerixafor was administered. Between 1995 and 2003 cyclophosphamide priming was used in most cases. Patients received melphalan 140 mg/m2 as a single dose given intravenously on day -5. TBI was administered in fractionated doses of 150 cGy between days -4 and -1 (total dose 12 Gy). Peripherally harvested stem cells were infused on day 0. Standard supportive measures were followed. Log-rank test and Kaplan-Meier curves were used to calculate overall survival (OS) and progression-free survival. Significance levels were standard (p<0.05). The expected survival for each patient was compared with data from the Louisiana Tumor Registry (matched with 5 year age interval and 4 year time of diagnosis interval). Results The OS from the date of diagnosis is shown in Fig. 1 (84.2 months). The mean survival from date of transplant to death or last follow-up is 70.1 months. No significant differences in OS were observed according to gender, race, age at transplant, or initial stage of disease. No significant differences were observed when patients transplanted in remission (CR, sCR or VGPR) were compared with patients with partial remission, stable or progressive disease. Patients treated more recently (2006-2013) had a trend to a longer survival compared with the earlier period (1995-2005). Seven out of 8 patients who were not in CR achieved CR post-transplant. The d100 survival in the earlier period was 83%, in the later period 97%. The 1 year survival increased from 72% in the earlier period to 91% in the later period. When the survival of patients transplanted at our center is compared with the observed survival of all MM patients in Louisiana, a dramatic difference becomes apparent (median survival 27 months versus 84 months, see Figure 1). Second malignancies were documented in 3 (6%) of our patients (T-cell lymphoma, renal cell carcinoma, possible myelodysplastic syndrome). Conclusion: Mel-TBI conditioning results in long-term survival, especially if the early toxicity associated with total body irradiation is ameliorated. The survival reported in this study is almost twice as reported by Moreau et al. The improvement is in large part due to salvage treatments and improved supportive care. However, MEL-TBI may be superior in certain subgroups of patients. We plan to perform a larger study comparing MEL-TBI to MEL only with risk stratification and to investigate the possible interaction between cyclophosphamide priming and early toxicity. According to our data, MEL-TBI does not result in increased second malignancies. The survival of patients who underwent transplant with MEL-TBI is superior to patients in a population-based registry (matched for age and time of treatment). Figure 1 Kaplan-Meier survival distribution of patients treated by autologous transplantation with MEL-TBI (green curve) compared with registry data (blue curve) from time of diagnosis to last follow-up or death Figure 1. Kaplan-Meier survival distribution of patients treated by autologous transplantation with MEL-TBI (green curve) compared with registry data (blue curve) from time of diagnosis to last follow-up or death Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document